http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

Ache Line Extension

RNS


RNS Number : 1350G

Oxford Pharmascience Group PLC

04 June 2013




Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience announces line extension for Brazil



Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces that it has agreed a line extension in Brazil with its Brazilian partner Aché Pharmaceuticos (Aché) for a new version of its calcium and vitamin D chew marketed under the brand name Inellare.

Sales to Aché of this new format are expected to begin in Q3 2013.



Nigel Theobald, Chief Executive Officer of Oxford Pharmascience commented,

"Our chew business in Brazil continues to grow strongly and the addition of a new version of our calcium product in the Brazilian market shows both the commitment of our partner and the ongoing potential for the range."

Oxford Pharmascience (LON:OXP), which specialises in reformulating tried and tested medicines, has agreed a line extension in Brazil with its Brazilian partner Aché Pharmaceuticos.

The deal is for a new version of Oxford’s calcium and vitamin D chew marketed under the brand name Inellare.

Broker N+1 Singer speculated that the new line being introduced is a sugar-free version of the calcium and vitamin D chew.

As it had already forecast this development, it is making no changes to its estimates, adding that it expects both the sugar and sugar-free versions of the chew to achieve modest growth, with minimal cannibalisation of market share.

“This morning’s news is evidence of Oxford Pharmascience continuing to deliver, with on-going progress being made in all three of its technology platforms,” it said.

“We maintain upbeat about the group and believe it is capable of becoming a major player in the re-formulation market. We recently upgraded our intrinsic value per share to 9.2p on the back of the successful proof of concept data with OXP zero and await further updates on the group’s development progression.”

Interesting post today on the other bulletin board by a shareholder who attended the AGM.

RNS Number : 5335J
Oxford Pharmascience Group PLC
17 July 2013



Oxford Pharmascience Group plc



("Oxford Pharmascience" or "the Company")



Oxford Pharmascience appoints Head of Clinical Development



Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces it has appointed Sheryl Caswell as Clinical Development Manager. Sheryl will be responsible for leading and executing the company's clinical development strategy focused on the company's two main medicines reformulation programmes in NSAIDs and Statins with reduced side effects. Sheryl will be a member of Oxford Pharmascience's management team reporting to Marcelo Bravo, chief technology officer.

Sheryl has more than 15 years of experience developing and executing global clinical programs for novel and first-in-class products from Phase I through Phase IV, with particular experience in early phase clinical development. Most recently as Clinical Programme Lead at Biogen Idec Ltd, she led the clinical programmes of two of the company's product candidates in neurology. Prior to that she served as Programme Director and Director of Clinical Research for Plethora Solutions where she led the clinical function as well as had overall clinical development responsibility for early phase products.

"Sheryl Caswell is joining Oxford Pharmascience at an exciting time in the company's evolution. We are progressing to human proof of concept trials in both our NSAIDs and Statin programmes and Sheryl will play a key role in making this happen," said Marcelo Bravo, Chief Technology Officer. "We look forward to leveraging Sheryl's extensive global clinical development experience as we advance our two main programmes in reformulation of NSAIDs and Statins with reduced side effects".

The road to market for most drugs is a long and arduous one, but the signs at Oxford Pharmascience (LON:OXP) are that everything is proceeding to plan, according to N+1 Singer.

The pharmaceutical company announced on Tuesday that industry veteran Sheryl Caswell has joined the company as clinical development manager, to oversee the company's clinical development strategy.

House broker N+1 Singer said: “The new appointment is an indication of the next phase of the group’s existing development plan, with progress towards human proof of concept trials in both the NSAIDs and statin programmes continuing as anticipated.”

The broker reiterated its 9.2p intrinsic value per share number for Oxford, saying it remains upbeat about the company, which it believes “is capable of becoming a major player in the reformulation market.”

Option with UCL to Explore Further Compounds

RNS


RNS Number : 0548K

Oxford Pharmascience Group PLC

25 July 2013






Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience signs option with UCL to explore further compounds.



Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that it has signed an option agreement with UCL ("University College London" to investigate 53 further compounds that it could potentially commercialise using UCL's Phloral™ technology.



Following closely working with UCL on the Company's program for Atorvastatin and Simvastatin, it has identified a further 53 compounds which might benefit from reformulation using Phloral™ to reduce their associated side effects.



The Company has agreed an option period until March 2014 to investigate the potential for these compounds with a further option period for another year to explore more thoroughly those compounds that it will identify to have the greatest commercial and clinical potential.





Nigel Theobald Chief Executive of Oxford Pharmascience commented



"Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programs for NSAIDs (non steroidal anti inflammatory drugs) and Statins.



There are many other drugs widely used where side effects reduce the tolerance or compliance in patients. This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programs.



We are committed to building a strong portfolio of reformulated drugs to deliver the high returns of new drug development but without the high risks."

Oxford Pharmascience extends collaboration with UCL
By Philip Whiterow July 25 2013, 8:11am The new agreement gives Oxford Pharma an option over a further 53 compounds.The new agreement gives Oxford Pharma an option over a further 53 compounds.

Drug delivery specialist Oxford Pharmascience (LON:OXP) has extended its collaboration with University College London (UCL) in the statins market.

The new agreement gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the university’s Phloral technology.

The company, which specialises in making drugs easier to take, is already working with UCL on re-formulations of generic statins Atorvastatin and Simvastatin to reduce their side effects.

The new deal gives Oxford Pharma until March next year to investigate the potential for the 53 compounds with an option to work for another year on those that have the best commercial and clinical potential.

Nigel Theobald, Oxford Pharma’s chief executive, said: "Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programs for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.

“There are many other drugs widely used where side effects reduce the tolerance or compliance in patients.

“This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.”

It all sounds very promising, dreamcatcher. Fortunately I don't have to take painkillers or drugs of any kind on a regular basis, but even very mild painkillers upset my gut. I have friends who need various drugs to alleviate medical conditions and the side effects are not pleasant.

when can AIM shares be added to ISAs [i know its Autumn but not sure when datewise] and will it be all AIM shares or just certain ones[ie the larger companies] as i would like to add these and SAR to my ISA.

Alex

See if this helps rob.

http://citywire.co.uk/money/qanda-aim-shares-and-isas/a690692

Oxford Pharmascience's new UCL deal is a "win-win"
By John Harrington July 25 2013, 12:44pm The compounds being looked at are already on the market, which means the route to market for new variations should be relatively swift.The compounds being looked at are already on the market, which means the route to market for new variations should be relatively swift.

Drug delivery specialist Oxford Pharmascience (LON:OXP) has extended and deepened its collaboration with the University College London (UCL) and the university's well-regarded Phloral technology.

The new agreement gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the university’s know-how.

The company is already working with UCL on re-formulations of generic statins Atorvastatin and Simvastatin to reduce their side effects, and the new deal will see Oxford Pharma get first pick of a different batch of compounds.

“It’s the same technology that we’re licensing,” Nigel Theobald, Oxford Pharma’s chief executive, explained to Proactive Investors. That technology is a more effective drug delivery system that, in essence, achieves the same effect as regular drugs but with smaller dosages.

“There are lots of other drugs out there where there are side-effects caused from metabolism in the Cy [Cytochrome] P450 system,” he added. Cy-P450 enzymes are essential for the metabolism of many medications.

The new deal gives Oxford Pharma until March next year to investigate the potential for the 53 compounds with an option to work for another year on those that have the best commercial and clinical potential.

In fact, the company has already been doing some preliminary work on the testing, indicating that the relationship between UCL and Oxford Pharma is a healthy and potentially productive one.

Speaking about the compounds, Theobald said: “Some of them could have a very strong commercial need, and a very strong clinical need, and could work very well with our technology. All three of those things we are investigating.”

Theobald said that Oxford Pharma and UCL have yet to agree on the terms of any licensing arrangement that arises from the new deal have, but they are likely to be similar to the terms already agreed for statins.

“We’re just pushing on and trying to get the greatest commercial opportunities out of it [the relationship]. They’re delighted, and we’re delighted. It’s a good win-win,” Theobald said.

Just as importantly, the deal closes the door to any competitor that might have been interested in getting a look at these compounds.

“Having already told the world how to do it, we want to make sure that people don’t try to get in ahead of us,” the Oxford Pharma chief executive said.

It is classic Oxford Pharmascience procedure, exploring and developing better options of existing drugs.

“All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,” Theobald revealed.

"Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programmes for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.

“There are many other drugs widely used where side effects reduce the tolerance or compliance in patients.

“This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.”

Theobald was keen to emphasise that last point about the new deal not being a distraction to the company’s existing work programmes.

“The redevelopment work that we do will be quick and it will be relatively cheap,” Theobald said.

Shares in Oxford Pharmascience were up 1.8% at 3.74p in lunch-time trading.

SMALL CAPS SHARE TIPS: Uni tie-up and statins breakthrough gives Oxford Pharmascience a shot in the arm

By John Harrington, Proactive Investors

PUBLISHED: 17:43, 29 July 2013 | UPDATED: 18:10, 29 July 2013





Shares in Oxford Pharmascience continue to perform well as investors sharpen their focus on its innovative work with University College London.

Investors appear keen to back the company which has just inked a new deal to extend and deepen its collaboration with UCL and the university's well-regarded Phloral technology.

The idea is that together they will apply innovative drug delivery technology, which will allow more effective dosing, and hopefully reduce side-effects as a result. The partners have already had success with this kind of work on statins, a cholesterol busting drug.




Under the microscope: Oxford Pharmascience has deals in place to commercialise further UCL scientific breakthroughs.

One of the major problems with statins is that many users suffer unpleasant side effects such as inflammation and muscle damage.

A lower dosage would result in fewer side effects, but also, under normal circumstances, be less effective in lowering the patient’s cholesterol level.




However, Oxford Pharma has reformulated two of the most widely used generic statins, Atorvastatin and Simvastatin, which will allow them to be delivered to the colon where they are more effectively absorbed into the liver.

The new agreement, signed last week, gives Oxford Pharma an option over a further 53 compounds that it could commercialise using the UCL’s know-how.

The new deal will see Oxford Pharma get first pick of a different batch of compounds.


.
'It’s the same technology that we’re licensing,' Nigel Theobald, Oxford Pharma’s chief executive, explained to Proactive Investors.

Oxford Pharma has until March next year to investigate the potential for the 53 compounds and it can then spend another year assessing those with the best commercial and clinical potential.

Speaking about the compounds, Theobald said: 'Some of them could have a very strong commercial need, and a very strong clinical need, and could work very well with our technology. All three of those things we are investigating.'

Oxford Pharma and UCL have yet to agree on the terms of any licensing arrangements should these programmes lead to commercial products, but it is likely that any deal would be similar to the terms to other existing terms for statins.



Hargreaves Isa Guide 2

'We’re just pushing on and trying to get the greatest commercial opportunities out of it [the relationship]. They’re delighted, and we’re delighted. It’s a good win-win,' Theobald said.

Just as importantly, the deal closes the door to any competitor that might have been interested in getting a look at these compounds.

'Having already told the world how to do it, we want to make sure that people don’t try to get in ahead of us.'

It is classic Oxford Pharmascience procedure, exploring and developing better options of existing drugs.

'All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,' Theobald revealed.

'Our focus on reformulating existing medicines to make them safer and easier to take is now gathering strong momentum with our programmes for NSAIDs (non-steroidal anti-inflammatory drugs) and statins.

'There are many other drugs widely used where side effects reduce the tolerance or compliance in patients. This option allows us to explore a range of potential drug candidates which fit with this strategy without taking our eyes off the existing programmes.'

Theobald was keen to emphasise that last point about the new deal not being a distraction to the company’s existing work programmes.

'The redevelopment work that we do will be quick and it will be relatively cheap,' Theobald said.

RNS
RNS Number : 8525K
Oxford Pharmascience Group PLC
02 August 2013



Oxford Pharmascience Group plc



("Oxford Pharmascience" or "the Company")





Oxford Pharmascience establishes Scientific Advisory Board





Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces establishment of a scientific advisory board to support its medicines reformulation programme.



The Scientific Advisory Board shall consist of the Chief Technology Officer and independent world class experts, providing a broad range of expertise in both basic and clinical sciences, as well as technologies. The Scientific Advisory Board will function as a broadly knowledgeable and objective group of scientists and non-scientists to consider and report periodically to the Board on matters relating to the investment in the Company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the Company's business.



As a first step, the company is appointing Professor Bill Dawson to serve on the scientific advisory board. Bill Dawson retired from Eli Lilly and Co in 1996 after 27 years where he was Research Director for 14 years and took 15 compounds into development, two of which reached the market. Bill is currently a non-executive director of Proteome Sciences Plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards. He is Chairman of the Academy of Pharmaceutical Sciences and a Visiting Professor at the UCL School of Pharmacy. He is a member of the Expert Panel advising the Stevenage Bioscience Catalyst.



Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented, "The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes. Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D programmes is invaluable as we enter a new stage as a company. We plan to continue building the Scientific Advisory Board with further appointments in the coming months."

Oxford Pharmascience sets up Scientific Advisory Board
By John Harrington


August 02 2013, 1:18pm Professor Dawson is chairman of the Academy of Pharmaceutical Sciences and a visiting professor at the UCL School of Pharmacy. He is also a member of the Expert Panel advising the Stevenage Bioscience Catalyst.Professor Dawson is chairman of the Academy of Pharmaceutical Sciences and a visiting professor at the UCL School of Pharmacy. He is also a member of the Expert Panel advising the Stevenage Bioscience Catalyst.

Medicines reformulation specialist Oxford Pharmascience (LON:OXP) is setting up what it describes as a “world class” Scientific Advisory Board to support its development programme.

Marcelo Bravo, chief technology officer of Oxford Pharmascience, will be on the Scientific Advisory Board, as will a number of independent experts, starting with Professor Bill Dawson, a former leading light at US pharmaceuticals giant Eli Lilly.

Professor Dawson retired from Eli Lilly in 1996 after 27 years where he was director of Research for 14 years. During his time at the US pharmaceuticals company he took 15 compounds into development, two of which reached the market.

He is currently a non-executive director of Proteome Sciences plc, and Antitope Ltd as well as a member of a number of corporate Scientific Advisory Boards.

Further appointments to this team of experts will be made in the coming months. The idea is for the board to have a broad range of skills, experiences and fields of expertise, extending beyond the world of science into areas such as technology.

Oxford Pharmascience said the Scientific Advisory Board will report periodically to the Oxford Pharma board on matters relating to the investment in the company's research and development and technology initiatives. The Scientific Advisory Board may also suggest specialist advisers and work closely with them to help progress elements of the company's business.

"The establishment of a world class Scientific Advisory Board to guide the company's development programme will help us accelerate progress into specific medicine development programmes,” Bravo explained.

“Professor Dawson's experience in the design, selection and progression of new medicines through optimal R&D [research & development] programmes is invaluable as we enter a new stage as a company,” he added.

The creation of this brains trust follows a week after the drug delivery specialist extended and deepened its collaboration with the University College London (UCL) and the university's well-regarded Phloral technology.

The deal gave Oxford Pharma first dibs on 53 compounds that it could commercialise using the university’s know-how.

“All of the compounds are on the market. A good chunk of them are already generic, and some are coming off-patent very soon,” Oxford Pharmascience chief executive Nigel Theobald revealed to Proactive Investors last week.

In keeping with Oxford Pharmascience's normal strategy, the company will be looking to see if it can reformulate the compounds, making them more effective and therefore suitable for commercial release.

and ISA-able from 05 Aug 2013

Did you see post 73 rob, hope it helped.

DC, it did thanks though i got the date off of another thread somewhere on MoneyAM. i can't remember which one though.

roll on the 5th August

Alex

Only four days robertalexander. :-))

Speciality pharma group Oxford Pharmascience's (LON:OXP) establishment of a Scientific Advisory Board and the appointment of Professor Bill Dawson indicate the progression of the group’s existing development plan remains on track, said house broker N+1 Singer.

"Momentum of moving towards human proof of concept trials in both the NSAIDs and Statin programmes continues to build. We re-iterate our upbeat view and believe the group is capable of becoming a major player in the reformulation market. We retain our 9.2p intrinsic value per share." Shares were 3.7p today.



http://www.proactiveinvestors.co.uk/columns/broker-spotlight/13757/broker-round-up-part-2-genel-advanced-computer-leni-gas-oil-13757.html

On the move up today as some large buyers appeared earlier on.
The bounce is from support